New EU-Funded Consortium Aims To Develop Targeted Cancer Vaccines
This article was originally published in The Pink Sheet Daily
Executive Summary
A clinical trial is expected to start in the U.S. and Europe in 2014 of an individualized approach to developing a cancer vaccine for glioblastoma patients.
You may also be interested in...
European Notebook: Renewed Calls For German Pricing Law Changes, Spain Gauges The Value Of Innovation
German health insurers run a cash surplus in the first quarter; Celesio CEO dismissed; Bayer celebrates 150 years; Spain wants to evaluate value for drug pricing; France's drug spend declines in 2012, and more.
Melanoma Success Paves Way For Path Of Gold In Cancer Immunotherapy
Phase I data for immune checkpoint molecules in melanoma from Bristol, Roche and Merck were a major highlight of the ASCO 2013 annual meeting. Considering potential application in many cancers regardless of genetic mutations, some analysts are predicting billions in future sales.
ScanCell’s DNA Plasmid-Cancer Vaccine Shows Promise In Melanoma
ScanCell Holdings’ potential DNA cancer vaccine, which is administered via an electrical field-driven device, shows preliminary evidence of efficacy in late-stage melanoma patients.